Long-term survival in primary breast cancer: Correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy

Medical Science Monitor

Volumn 10, Issue 10, 2004, Pages

  Chrapusta, Stanisław J ^a,c   Giermek, Jerzy ^b   Pieńkowski, Tadeusz ^b  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Adjuvant antiestrogen; Estrogen receptor alpha; Immunohistochemical assay; Monoclonal antibody; Radioligand assay; Steroid receptor assay

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR ALPHA; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; RADIOLIGAND; STEROID RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG EFFECT; FEMALE; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MENOPAUSE; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TIME FACTORS;

EID: 7044260461     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Colditz GA: Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst, 1998; 90: 814-23
2. Liehr JG: Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Human Reprod Upd, 2001; 7: 273-81
3. Jones DA, Cho J, Salamon E, Stefano GB: Risk factors for breast cancer and the prognosis of African American women; estrogen's role. Med Sci Monit, 2003; 9(6); RA131-RA139
4. Rajkumar L, Guzman RC, Yang J et al: Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments. Breast Cancer Res, 2004; 6: R31-37
5. Knight WA, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptors as independent prognostic factor for recurrence in breast cancer. Cancer Res, 1977; 37: 4669-71
6. DeSombre ER, Jensen EV: Estrophilin assays in breast cancer, quantitative features and application to mastectomy specimen. Cancer, 1980; 46: 2783-88
7. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL: The value of es trogen and progesterone receptors in the treatment of breast cancer. Cancer, 1980; 46: 2884-88
8. Leake R: Prediction of hormone sensitivity - the receptor years and onwards. Endocr Relat Cancer, 1997; 4: 289-96
9. McGuire WL, Clark GM: The prognostic role of progesterone receptors in human breast cancer. Semin Oncol, 1983; 10: 2-6
10. Fuqua SA, Schiff R. Parra I et al: Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res, 2003; 63: 2434-39
11. Lippman ME, Allegra JC: Quantitative es trogen receptor analysis: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer, 1980; 46: 2829-34
12. Vollenweider-Zerargui L, Barrelet L, Wong Y et al: The predictive value of es trogen and progesterone receptors concentrations on the clinical behavior of breast cancer in women. Cancer, 1986; 57: 1171-80
13. Thorpe SM, Rasmussen BB, Mouridsen HT et al: Prognostic value of steroid hormone receptors: Multivariate analysis of systemically untreated patients with node negative primary breast cancer, Cancer Res, 1987; 47: 6126-33
14. Anderson WF, Chu KC, Chatterjee N et al: Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol, 2001; 19: 18-27
15. Bardou VJ, Arpino G, Elledge RM et al: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol, 2003; 21: 1973-79
16. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat, 2003; 78: 105-18
17. Floiras JL, Hacene K, Turpin F, Spyratos F: Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values? Int J Biol Markers, 2000; 15: 135-38
18. Struse K, Audretsch W, Rezai M et al: The estrogen receptor paradox in breast cancer: association of high receptor concentrations with reduced overall survival. Breast J, 2000; 6: 115-25
19. Shek LL, Godolphin W: Survival with breast cancer: the importance of estrogen receptor quantity. Eur J Cancer Clin Oncol. 1989; 25: 243-50
20. Greene GL, Sobel NB, King WJ, Jensen EV: Immunochemical studies of estrogen receptors. J Steroid Biochem, 1984; 20: 51-56
21. DeSombre ER, Thorpe SM, Rose C et al: Prognostic usefulness of estrogen receptor immunochemical assays for human breast cancer. Cancer Res. 1986; 46: 4256S-64S
22. McClelland RA, Berger U, Miller S et al: humunocytochemical assay for estrogen receptor: Relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res, 1986; 46: 4241S-43S
23. DeSombre ER, Greene GL, King WJ, Jensen EV: Estrogen receptors, antibodies, and hormone dependent cancer. In: "Hormones and Cancer: Proceedings of the International Symposium on Hormones and Cancer, Buenos Aires, Argentina, May 9-13, 1983" (Gurpide E, ed.), AR Liss, Inc. New York, 1984; 1-21
24. Biesterfeld S, Schroder W, Steinhagen G et al: Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information. Anticancer Res. 1997; 17: 4723-29
25. Chang J, Powles TJ, Allred DC et al: Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res, 2000; 6: 616-21
26. Chrapusta S, Sieinski W, Konopka B et al: [Concentrations of estrogen and progestagen receptors in the uterine myomas of women in the course of menstrual cycle.] Nowotwory, 1988; 38: 23-28
27. Chrapusta S, Konopka B, Paszko Z et al: Immunoreactive and estrogen-binding estrogen receptors, and progestin receptor levels in uterine leiomyomata and their parental myometrium. Eur J Gynaecol Oncol, 1990; 11: 275-81
28. Kuiper GG, Lemmen JC, Carlsson B et al: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology, 1998; 139: 4252-63
29. Brouillet JP, Dujardin MA, Chalhos D et al: Analysis of the potential contribution of estrogen receptor (ER) beta in ER cytosolic assay of breast cancer. Int J Cancer, 2001; 95: 205-8
30. Remmele W, Hiklebrand U, Hienz HA et al: Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch. 1986; 49: 122-47
31. Coradini D, Daidone MG: Biomolecular prognostic factors in breast cancer. Curr Opin Obstet Gynccol, 2004; 16: 49-55
32. Ciocca DR, Elledge R: Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine, 2000; 13: 1-10
33. Duffy MJ: Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem, 2001; 34: 347-52
34. Goldhirsch A, Wood WC, Gelber RD et al: Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol, 2003; 21: 3357-60
35. Stierer M, Rosen H, Weber R et al: Comparison of immunohistochemical and biochemical measurement of steroid receptors in primary breast cancer: evaluation of discordant findings. Breast Cancer Res Treat, 1998; 50: 125-34
36. Costa SD, Lange S, Klinga K et al: Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer-results of the analysis of 670 patients with 11 years of follow-up. Eur J Cancer, 2002; 38: 1329-34
37. McCann J: Better assays needed for hormone receptor status, experts say. J Natl Cancer Inst, 2001; 93: 579-80
38. Shao W, Brown M: Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res, 2003; 6: 39-52
39. Panithiyil S, Parmar H, Kerekatte V et al: Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res, 2004; 64: 423-28
40. Elledge RM, Green S, Pugh R et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group study, Int J Cancer, 2000; 89: 111-17
41. Harvey JM, Clark GM, Osborne CK. Allred DC: Estrogen receptor status by immunochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, 1999; 17: 1474-81
42. Speirs V: Oestrogen receptor β in breast cancer: good, bad or still too early to tell? J Pathol, 2002; 197: 143-47
43. Nakopoulon E, Lazaris AC, Panayotoponlou EG et al: The favourable prognostic value of oestrogen receptor beta immnnohistochemical expression in breast cancer. J Clin Pathol, 2004; 57: 523-28
44. Castagnetta L, Traina A, Agostara B et al: Ligand binding and cytochemical analysis of estrogen and progesterone receptors in relation to followup in patients with breast cancer. Ann NY Acad Sci, 2002; 963: 98-103
45. Lamy PJ, Pujol P, Thezenas S et al: Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy. Breast Cancer Res Treat, 2002; 76: 65-71
46. Agrimonti F, Berruto GP, Fornaro D et al: Quality control for estrogen and progesterone receptor assay in human breast cancer: the influence of computation methods on intra and interlaboratory variability. Tumori, 1985; 71: 597-602
47. Goldhirseh A, Gelber RD. Yothers G et al: Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr, 2001; 30: 44-51
48. Aebi S, Gelber S, Castiglione-Gertsch M et al: Is chemotherapy alone-adequate for young women with oestrogen receptor-positive breast cancer? Lancet, 2000; 355: 1869-74
49. Coradini D, Daidone MG, Boracchi P et al: Time-dependent relevance of steroid receptors in breast cancer. J Clin Oncol, 2000; 18: 2702-9
50. Fuqua SA: The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia, 2001; 6: 407-17
51. Demichteli R, Valagussa P, Bonadonua G: Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy. Breast Cancer Res Treat, 2002; 75: 127-34
52. Buzdar AU: Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. Clin Cancer Res, 2004; 10: 355S-61S
53. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial, Lancet, 1987; 2: 171-75
54. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet, 1998; 351: 1451-67
55. [No authors listed]. Adjuvant therapy for breast cancer. NIH Consensus Statement, 2000; 17: 1-35
56. Fisher B, Jeong JH, Dignam J et al: Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr, 2001; 30: 62-66
57. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph nude status, and survival in 24, 740 breast cancer cases. Cancer, 1989; 63: 181-87
58. Been ken SW, Urist MM, Zhang Y et al: Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg, 2003; 237: 732-39
59. Gebauer G, Fehm T, Lang N, Jager W: Tumor size, axillary lymph node status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery. Breast Cancer Res Treat, 2002; 75: 167-73
60. Van der Wal BC, Butzelaar RM, van der Meij S, Boermeester MA: Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol, 2002; 28: 481-89
61. Biganzoli E, Boracchi P, Coradini D et al: Prognosis in node-negative primary breasl cancer: a neural network analysis of risk profiles using routinely assessed factors. Ann Oncol, 2003; 14: 1484-93
62. Sartorius CA, Shen T, Honwitz KB: Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res Treat. 2003; 79: 287-99
63. Hopp TA, Weiss HL, Hilsenbeck SG et al: Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res, 2004; 10: 2751-60